COMPOSITION FOR SUPPRESSING MUSCULAR ATROPHY

• US 20190314443A1
• Filed: 12/04/2017
• Published: 10/17/2019
• Est. Priority Date: 12/05/2016
• Status: Active Grant

• Current Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: SHIMIZU, Muneshige, SHIOKAWA, Akina, HAMADA, Koichiro, MAGATA, Kiyohiko, NIKAWA, Takeshi, MAITA, Ayako
• Granted Patent: US 11,331,366 B2
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/18 Peptides; Protein hydrolysates
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis

Abstract

The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.

Claims

1. A method for suppressing muscular atrophy, comprising administering to a subject one or more peptides selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK;

the group consisting of dipeptides comprising F; and

the group consisting of dipeptides DI, IY, YN, and NP.

2. The method according to claim 1, wherein the one or more peptides are selected from the group consisting of dipeptides comprising F.

3. The method according to claim 1, wherein the one or more peptides are selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK;

and

the group consisting of dipeptides DI, DF, IF, FN, FY, IY, YN, and NP.

4. The method according to claim 1, wherein the one or more peptides comprise FN.

5. The method according to claim 1, for preventing or treating a disease with muscular atrophy.

6. The method according to claim 5, wherein the disease is sarcopenia, disuse muscle atrophy, muscular dystrophy, diabetic amyotrophy, cachexia, steroid myopathy, drug induced myopathy, rhabdomyolysis, myasthenia gravis, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, or stress urinary incontinence.

7. The method according to claim 1, wherein the one or more peptides are comprised in a pharmaceutical product.

8. A method for improving low muscle mass, comprising administering to a subject one or more peptides selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK;

the group consisting of dipeptides comprising F; and

the group consisting of dipeptides DI, IY, YN, and NP.

9. The method according to claim 8, wherein the one or more peptides are selected from the group consisting of dipeptides comprising F.

10. The method according to claim 8, wherein the one or more peptides are selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK;

and

the group consisting of dipeptides DI, DF, IF, FN, FY, IY, YN, and NP.

11. The method according to claim 8, wherein the one or more peptides comprise FN.

12. The method according to claim 8, for improving stress urinary incontinence.

13. The method according to claim 8, for improving urine leakage.

14. The method according to claim 8, wherein the one or more peptides are comprised in a food or drink.